Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Tesamorelin (TESA) is a growth hormone peptide, at the fda approved stage in the published literature. FDA-approved GHRH analog for HIV-associated lipodystrophy. Reduces visceral adipose tissue while maintaining metabolic parameters.
FDA-approved GHRH analog for HIV-associated lipodystrophy. Reduces visceral adipose tissue while maintaining metabolic parameters.
| Research Status | FDA approved |
|---|---|
| Half-Life | 26-38 minutes |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 2 mg daily |
Synthetic GHRH analog with trans-3-hexenoic acid modification, stimulates natural GH release.
FDA-approved GHRH analog for HIV-associated lipodystrophy. Reduces visceral adipose tissue while maintaining metabolic parameters.
Synthetic GHRH analog with trans-3-hexenoic acid modification, stimulates natural GH release.
Tesamorelin is at the following stage in the published literature: FDA approved. All information is for research and educational purposes only.
Reported half-life: 26-38 minutes.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.